TBO-309
Phase 2Small molecule
TBO-309 is one of 28 small molecule programs targeting Stroke. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Activase
RochePreclinical
Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Alka-Seltzer
AAbbott
Preclinical
TBO-309
TThe Florey Institute of Neuroscience and Mental Health
Phase 2
Inderal
Mylan Pharmaceuticals IncPreclinical
Botulinum Toxin a
GSKPreclinical
Anticoagulant
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TBO-309. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details